Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector

被引:61
作者
Lee, JW
Hampl, M
Albert, P
Fine, HA
机构
[1] NINDS, Neurooncol Branch, NCI, NIH, Bethesda, MD 20892 USA
[2] Natl Canc Inst, Biometr Res Branch, DCTD, Bethesda, MD USA
来源
NEOPLASIA | 2002年 / 4卷 / 04期
关键词
TRAIL; apoptosis; adenoviral vectors; gene therapy; cancer therapeutics;
D O I
10.1038/sj.neo.7900245
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in a variety of transformed cell lines, but generally spares most normal cells. Transduction by an adenoviral vector expressing human TRAIL cDNA (Ad.TRAIL-GFP) resulted in both direct tumor cell killing as well as a potent bystander effect through presentation of TRAIL by transduced normal cells. Administration of Ad.TRAIL-GFP significantly prolonged survival of mice harboring either intracerebral glioblastomas or breast carcinoma-induced peritoneal carcinomatosis. Additionally, TRAIL induced prolonged transgene expression in normal tissue, presumably as a result of diminished immune-mediated destruction of vector - transduced cells. Taken together, these data suggest that vector-mediated transduction of TRAIL may represent an effective strategy for cancer gene therapy.
引用
收藏
页码:312 / 323
页数:12
相关论文
共 32 条
[1]   Apoptosis control by death and decoy receptors [J].
Ashkenazi, A ;
Dixit, VM .
CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) :255-260
[2]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[3]   A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION [J].
BELLGRAU, D ;
GOLD, D ;
SELAWRY, H ;
MOORE, J ;
FRANZUSOFF, A ;
DUKE, RC .
NATURE, 1995, 377 (6550) :630-632
[4]   In vitro expansion of a multipotent population of human neural progenitor cells [J].
Carpenter, MK ;
Cui, X ;
Hu, ZY ;
Jackson, J ;
Sherman, S ;
Seiger, Å ;
Wahlberg, LU .
EXPERIMENTAL NEUROLOGY, 1999, 158 (02) :265-278
[5]   Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy [J].
Chinnaiyan, AM ;
Prasad, U ;
Shankar, S ;
Hamstra, DA ;
Shanaiah, M ;
Chenevert, TL ;
Ross, BD ;
Rehemtulla, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) :1754-1759
[6]   Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials [J].
Dewey, RA ;
Morrissey, G ;
Cowsill, CM ;
Stone, D ;
Bolognani, F ;
Dodd, NJF ;
Southgate, TD ;
Klatzmann, D ;
Lassmann, H ;
Castro, MG ;
Lowenstein, PR .
NATURE MEDICINE, 1999, 5 (11) :1256-1263
[7]   APOPTOSIS IN CANCER-THERAPY - CROSSING THE THRESHOLD [J].
FISHER, DE .
CELL, 1994, 78 (04) :539-542
[8]  
Giovarelli M, 1999, J IMMUNOL, V163, P4886
[9]   FAS LIGAND-INDUCED APOPTOSIS AS A MECHANISM OF IMMUNE PRIVILEGE [J].
GRIFFITH, TS ;
BRUNNER, T ;
FLETCHER, SM ;
GREEN, DR ;
FERGUSON, TA .
SCIENCE, 1995, 270 (5239) :1189-1192
[10]   Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily [J].
Gruss, HJ .
INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, 1996, 26 (03) :143-159